Gregg Bresner
About Gregg Bresner
Gregg A. Bresner, age 58, is President and Chief Investment Officer of CĪON Investment Corporation and an officer of CĪON Investment Management (CIM), serving since 2016. He brings 25+ years across leveraged finance, investment management, and investment banking, including roles at Wasserstein Perella (M&A), Bankers Trust/Deutsche Bank (Financial Sponsors), co-founder of Briscoe Capital Management and portfolio manager of the Fairfield Briscoe Senior Capital Fund, Managing Director at Plainfield Asset Management, co-founder of Tyto Capital (private debt/equity), and operating CFO of JDS Therapeutics (2012–2016). He holds a B.S. magna cum laude from Rensselaer Polytechnic Institute, an MBA from Columbia Business School (Beta Gamma Sigma), and is a CFA charterholder . CĪON’s proxy does not disclose executive performance metrics (TSR, revenue/EBITDA growth) tied to his compensation; executive officers receive no direct compensation from the Company, with services provided through CIM under advisory and administration agreements .
Past Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Wasserstein Perella & Co. | Investment banking – M&A | Early career | Advised middle‑market companies and PE sponsors on M&A, leveraged recapitalizations, and restructurings . |
| Bankers Trust Company / Deutsche Bank | Senior investment banker – Financial Sponsors Group | Pre-2003 | Sourced/structured leveraged senior, high yield, and mezzanine financings for PE sponsors . |
| Briscoe Capital Management | Co‑founder; portfolio manager, Fairfield Briscoe Senior Capital Fund | 2003–2006 | Actively managed ~100-issuer loan portfolio; raised/used ~$700 million of committed debt facilities with Citigroup and CIBC . |
| Plainfield Asset Management | Managing Director | 2006–2010 | Sourced/executed direct U.S. debt and equity investments across Plainfield funds . |
| Tyto Capital | Co‑founder | 2010–2012 | Originated/acquired private debt/equity investments in U.S. middle‑market companies . |
| JDS Therapeutics | Operating Chief Financial Officer | 2012–2016 | Led finance, accounting, capital raising, corporate development and HR; completed multiple capital raises, licensing transactions and acquisitions . |
| CĪON / CIM | President & CIO (CĪON); Senior Managing Director & CIO (CIM); member of CIM’s investment committee | Since Apr 2016 | Oversees investment operations and portfolio management for the BDC; appointed April 2016 . |
External Roles
| Organization | Role | Years | Strategic Impact |
|---|---|---|---|
| Public company boards (past 5 years) | None | N/A | No other public directorships held in the past five years . |
| CĪON Investment Management (advisor) | Senior Managing Director & CIO; investment committee member | Since 2016 | Advisor to the Company under investment advisory agreement; manages day‑to‑day investment operations . |
Fixed Compensation
Executive officers do not receive direct compensation from CĪON; services are provided by officers/employees of CIM per the advisory and administration agreements, with CĪON reimbursing CIM for allocable expenses. Accordingly, base salary, bonus, and perquisites for Mr. Bresner are not disclosed at the Company level .
Performance Compensation
The Company does not disclose executive performance incentive structures (RSUs/PSUs/options, performance metrics, weighting, or vesting) for Mr. Bresner, as executives are compensated by CIM rather than directly by CĪON. The compensation committee did not hold formal meetings in 2024 and does not produce a report on executive compensation practices since executives are not compensated by the Company .
Equity Ownership & Alignment
CĪON reports beneficial ownership for executive officers; Bresner’s holdings have increased over time and remain <1% of shares outstanding.
| Metric | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 |
|---|---|---|---|---|---|
| Shares beneficially owned | 0 | 25,099 | 46,099 | 52,099 | 64,599 |
| Shares outstanding (record date) | 56,958,440 | N/D | N/D | 53,565,154 | 52,591,682 |
| Ownership % of outstanding | 0.00% | N/D | N/D | ~0.097% (52,099 / 53,565,154) | ~0.123% (64,599 / 52,591,682) |
| Holding detail (2024 footnote) | 40,599 shares direct; 11,500 via investment retirement accounts (sole voting/investment power) | — | — | See footnote detail | — |
Additional alignment and risk notes:
- Policy prohibits directors and officers from engaging in hedging or monetization transactions without prior approval of the chief compliance officer, reducing potential misalignment from derivative hedges or margin monetization .
- No disclosure of pledged shares by Mr. Bresner; 2024 footnotes indicate retirement account holdings but not pledging .
Employment Terms
| Term | Detail |
|---|---|
| Appointment | Appointed Senior Managing Director & Chief Investment Officer effective April 18, 2016; also CIO of CIM and member of CIM’s investment committee . |
| Employment agreement | No individual employment or compensatory arrangements disclosed at Company level; executives compensated by CIM . |
| Severance / change‑of‑control | Not disclosed for individual executives. Advisory and administration agreements include indemnification/hold‑harmless provisions for CIM and affiliates under defined conduct standards . |
| Non‑compete / non‑solicit / garden leave | Not disclosed. |
| Related party transactions | None requiring disclosure under Item 404(a) at appointment; no family relationships . |
Compensation Committee Analysis
- Committee members: Robert A. Breakstone, Peter I. Finlay, Aron I. Schwartz, Earl V. Hedin, Catherine K. Choi, and Edward J. Estrada; all meet independence standards under SEC, 1940 Act, and NYSE .
- The compensation committee is responsible for determining or recommending compensation for executive officers, but as executives are not compensated by the Company, the committee did not hold formal meetings in 2024 and does not produce a compensation report .
- The advisory fee payable to CIM was approved by shareholders in 2021 and renewed annually by independent directors commencing in 2023 .
Board Governance
- Bresner is not a director of the Company; no board committee memberships or director compensation apply to him .
- Independent director compensation consists of cash retainers, meeting fees, and chair fees; no equity awards granted to directors for FY 2024 .
Investment Implications
- Alignment: Bresner holds a modest but rising direct stake (~0.12% of outstanding in 2025; ~0.097% in 2024), with holdings across direct and retirement accounts; the Company’s policy restricting hedging/monetization suggests limited alignment risk from derivatives or margin loans .
- Pay for performance: Executive compensation is at CIM, not disclosed at Company level; therefore, payout mechanics, performance metrics, and vesting cannot be evaluated—limiting visibility into individual incentives relative to TSR or portfolio performance .
- Retention risk: Tenure since 2016 across dual roles at CĪON/CIM and deep leveraged finance background point to continuity; absence of disclosed severance/CoC terms prevents assessment of exit economics but no Item 404 related‑party issues were noted at appointment .
- Trading signals: No evidence of pledging; policy constraints on hedging/monetization reduce forced‑selling pressure risk from margin activity. Ownership remains <1%, so personal transactions are unlikely to materially impact float, but patterns would require Form 4 monitoring to assess near‑term insider activity, which is not disclosed in proxies .